ReviewJAC-antimicrobial resistance2026
The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.
Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by metallo-β-lactamase (MBL)-producing gram-negative pathogens represent a formidable and emerging threat to public health. MBLs compromise the activity of carbapenems and many newly developed β-lactam/β-lactamase inhibitor agents, leaving few treatment options. Remarkably, these enzymes have disseminated globally at an unprecedented rate. Therapeutic management of MBL-producing pathogens remains a major challenge because the enzymes are not inhibited by currently available β-lactamase inhibitors, and most pathogens that harbour MBLs are equipped with mechanisms of resistance to all available antibiotic classes. Recent advances have elucidated the biochemical and structural function of diverse MBLs thereby improving the development of future antibiotics. In this review, we summarize the contemporary global epidemiology of clinically relevant MBLs, describe the molecular mechanisms driving their dissemination and evaluate current and emerging therapeutic strategies for infections caused by MBL-producing gram-negative pathogens including Enterobacterales,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.